510(k) device
PrecivityAD2 Test
C2N Diagnostics, LLC · Immunoassay Blood Test For Amyloid Pathology Assessment (SET, Class II) · First FDA decision Aug 19, 2026, newest Aug 19, 2026Alzheimer's disease and dementia
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "PrecivityAD2"
MAUDE reports
0
Brand "PrecivityAD2", since 2015
PubMed studies
12
Mentioning "PrecivityAD2"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PrecivityAD2 Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- PrecivityAD2 Test510(k)
K253240 · Decided Aug 19, 2026 · 324 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening Immunoassay Fecal-Occult Blood TestNational analysisReview closedCAG-00180NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "PrecivityAD2", any status and sponsor, newest update first.
No registered device study names "PrecivityAD2".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PrecivityAD2", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SET
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PrecivityAD2"[tiab]. The summary above synthesizes these.
- Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
Meyer MR, Kirmess KM, Eastwood S, et al. · Alzheimers Dement · 2024Validation Study, Research Support, N.I.H., Extramural
- The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease.
Hu S, Yu H, Gao J · Drug Discov Ther · 2025
- Editorial: Real-World Outcomes of Disease-Modifying Therapies Highlight the Need for Diagnostic Biomarkers in Early Alzheimer's Disease.
Parums DV · Med Sci Monit · 2025Editorial
- Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia.
Cody KA, Du L, Studer RL, et al. · Alzheimers Dement · 2025
- Implementation of an Alzheimer's Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study.
Monane M, Carlile RM, Johnson KG, et al. · J Pers Med · 2025
- Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer's disease.
Schlachetzki Z, Langford O, Zammit MD, et al. · Commun Med (Lond) · 2026
- Independent validation of the PrecivityAD2ࡊ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment.
Coppinger J, West T, Kirmess KM, et al. · medRxiv · 2025Preprint
- PrecivityAD2ࡊ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology.
Eastwood SM, Meyer MR, Kirmess KM, et al. · Diagnostics (Basel) · 2024
- Independent validation of the PrecivityAD2ࡊ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment.
Coppinger J, West T, Kirmess KM, et al. · NPJ Dement · 2025
- Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.
Monane M, Maraganore DM, Carlile RM, et al. · Diagnostics (Basel) · 2025
- P-tau217 and %p-tau217 exhibited superior diagnostic accuracy over other blood biomarkers in the initial assessment of individuals being diagnosed with mild cognitive impairment and Alzheimer's disease dementia.
Qiu Q, Qian W, Zhao W, et al. · J Alzheimers Dis Rep · 2026
- Two new blood tests for Alzheimer's disease.
Med Lett Drugs Ther · 2026
Other devices of this type
Also filed under product code SET.
- Elecsys Phospho-Tau (217P) PlasmaRoche Diagnostics · 510(k) 2026
- Lumipulse G pTau217/ß-Amyloid 1-42 Plasma RatioFujirebio Diagnostics,Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.